Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 112

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic...

Psychedelic Research Bulletin: April 2023

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic...

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Psychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph...

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH...

Algernon Pharmaceuticals Announces Closing of Rights Offering

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical...

Load more

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©